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IMPACT OF DISEASE AND MOBILIZING AGENTS ON INITIAL AND RE-
MOBILIZATION FAILURE
DiPersio, J.F.1, Smith, A.2, Sempek, D.2, Baker, A.2, Jiang, S.3,
Vij, P.1, Cashen, A.1, Westervelt, P.1 1Washington University, St.
Louis, MO; 2Barnes-Jewish Hospital, St. Louis, MO; 3University of
British Columbia, Vancouver, BC, Canada.
Background: High-dose chemotherapy with autologous stem cell
transplantation (ASCT) is a common treatment strategy in lymphoma
and myeloma, but no standard approach for the mobilization of
peripheral hematologic stem and progenitor cells has been estab-
lished. Levels of circulating CD34 cells, a surrogate marker for
mobilization efﬁciency, vary widely between pts, and may be inﬂu-
enced by disease state, prior therapy, and/or mobilization regimen.
Methods: The Washington University (St. Louis, MO) transplanta-
tion database includes clinical parameters from 407 MM, 562 NHL,
and 164 HD pts who received an ASCT (1995-2006). A retrospective
analysis of this large (1133 pts) population was conducted to deter-
mine factors associated with mobilization efﬁciency. Mobilization
failure was deﬁned as collection of  2  10^6 CD34 cells/kg
within 5 apheresis days. Statistical analysis included ANOVA with
Scheffe Test to determine differences in mobilization between the
various mobilization regimens (G-CSF, G-CSF/chemotherapy, G-/
GM-CSF, G-CSF/AMD3100). Results: All pts were included in the
analysis; 87% received G-CSF alone as the initial mobilization regi-
men. Mobilization failure rates are summarized in Table 1. NHL and
HD pts had a 4-fold higher failure rate than MM pts. G-CSF/chemo
increased the median CD34 yield compared to G-CSF alone, al-
though no obvious impact on the failure rate was noted in this
relatively small group of pts. Remobilization was associated with high
failure rates inNHL (79.2%), HD (77.1%), andMM (73.3%). Pooled
collections were2 10^6 CD34/kg in 33.6%, 37.1%, and 36.7%
of failed mobilizers, resp. G-CSF mobilization failures remobilized
with G-CSF plus AMD3100 collected signiﬁcantly more CD34
cells than G-CSF-failures remobilized with either G-CSF, G/GM-
CSF or G-CSF/chemo (1-way ANOVA: F(3, 233)  27.878, F0.5(3,
233).05  2.643, p  .0001). The compared groups did not signiﬁ-
cantly differ in initial mobilization efﬁciency with G-CSF (as deter-
mined by ANOVA and Scheffe Test). Conclusions: The mobiliza-
tion failure rate is substantially higher in NHL and HD pts than MM
pts. Pts who fail initial mobilization are likely to fail a 2nd mobiliza-
tion, regardless of disease state. As the combination of chemotherapy
to G-CSF may not be sufﬁcient to reduce failure rates, alternative
mobilization strategies are needed to improve HSPC collection, par-
ticularly in NHL/HD pts and failed mobilizers.
First mobilization failures ( 210^6 CD34/kg)
Mobilization
regimen N Failures
Median
yield
(x10^6)
Median
yield
(x10^6)
NHL G-CSF 471 26.5% 2.89 2.76-3.04
G-CSF/Chemo 35 22.9% 4.68 2.8-8.53
All* 564 28.7%
HD G-CSF 130 26.2% 3.01 2.75-3.37
G-CSF/Chemo 12 16.7% 5.38 2.35-9.52
All* 165 24.8%
MM G-CSF 386 6.5% 4.62 4.16-4.98
G-CSF/Chemo 17 5.9% 8.52 4.46-16.3
All* 409 6.6%
*Incl. pts mobilized w. alternative regimens
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AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANT USING
BUSULFAN, ETOPOSIDE, HIGH DOSE ARA-C, AND G-CSF PRIMING AS
CONDITIONING REGIMEN IN PATIENTS WITH ACUTE MYELOID LEU-
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de Segovia, Segovia, Spain; 20Hospital Universitario de Valladolid,
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Introduction: Conditioning regimens for autologous stem cell
transplantation (ASCT) in patients with acute myeloid leukemia
(AML) using more speciﬁc drugs for myeloid malignancies, such as
high-dose Ara-C (HD/Ara-C) and etoposide, have been increas-
ingly proposed as an alternative the classic BUCY schedule. Ob-
jectives: To analize safety and efﬁcacy of a conditioning regimen
combining busulfan, etoposide, HD/Ara-C, and G-CSF priming
for patients with AML in ﬁrst complete remission (CR1) under-
going ASCT. Patients: 147 patients with AML in CR1 after
induction and consolidation therapy with idarubicin or daunoru-
bicin and Ara-C following a ‘37’ schedule (PETHEMA LMA99
trial) underwent ASCT. They were 65 male and 82 female with a
median age 46 years. The median WBC and platelet counts at
presentation were 2  109/L (range, 0.04-193) and 59  109/L
(range, 7-578), respectively. According to the MRC criteria, 125
patients with available karyotype (85%) were classiﬁed as follows:
24 patients (19%) with standard risk, 87 patients (70%) with
intermediate risk, and 14 patients (11%) with high risk. Condi-
tioning regimen consisted of busulfan 1 mg/kg/6 hours on days -8
to -5, etoposide 20 mg/kg/day on days -4 and -3, Ara-C 3 g/m2/12
hours on days -3 and -2, and G-CSF 10 g/kg/day on days -9 to -2.
Results: Median time from diagnosis to ASCT was 6 months.
Median time to neutrophil count recovery above 0.5  109/L was
12 days (range, 5-90) and days of hospital stay was 29 days (range,
11-94). Thirty-two percent of patients had bacteremia, 9.5% doc-
umented infection without bacteremia , and 21% clinically docu-
mented infection without microbiological documentation. The
most relevant extrahematological toxicity was gastrointestinal tox-
icity grade 3 (36%). Event-free survival (EFS) at 4 years was
53%. Cytogenetics was the only variable associated to EFS: 62%
for standard-risk group, 52% for intermediate-risk group, and 24%
for high-risk group (P  0.0066). Five patients died due to ASCT
(transplant-related mortality, 3.4%). Four of them died before day
100 mainly due to infections, while the remaining patient died of
pulmonary thromboembolism 31 months after ASCT. Conclu-
sions: The conditioning regimen combining busulfan, etoposide,
HD/Ara-C, and G-CSF priming shows a high antileukemic efﬁ-
cacy in patients with AML in CR1. This regimen shows a moderate
toxicity proﬁle and low transplant-related mortality. Citogenetics
was the only prognostic factor identiﬁed for EFS.
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ARSENIC TRIOXIDE WITH ASCORBIC ACID AND HIGH-DOSE MELPHA-
LAN FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION FOR MULTIPLE MYELOMA
Qazilbash, M.H.1, Jindani, S.2, Gul, Z.2, Saliba, R.1, Hosing, C.1,
Mendoza, F.1, Qureshi, S.P.1, Weber, D.M.1, Wang, M.1, Flosser, T.1,
Couriel, D.P.1, Kebriaei, P.1, Popat, U.1, Alousi, A.M.1, De Lima, M.1,
Champlin, R.E.1, Giralt, S.A.1 1University of Texas - MD Anderson
Cancer Center, Houston, TX; 2Wayne State University/Detroit Medical
Center, Detroit, MI.
Backround: Arsenic trioxide (ATO) has been shown to be syner-
gistic with melphalan both in vitro and in vivo.We conducted a phase
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